Benzinga | Nov 17, 2020 06:35AM EST

Goldman Sachs Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $27

Goldman Sachs analyst Paul Choi initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $27.